文献速递妇科

低剂量与高剂量贝伐珠单抗在卵巢癌中的疗效与安全性比较:一项间接治疗比较

Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.
PubMed 文献 · Gynecol Oncol · 2025-03-24

本研究通过系统综述和间接治疗比较,评估低剂量(7.5 mg/kg 每三周)与高剂量(15 mg/kg 每三周)贝伐珠单抗联合化疗在卵巢癌中的疗效与安全性。纳入6项随机对照试验,主要分析显示两组在部分缓解、完全缓解、客观缓解率、疾病进展、临床获益、≥3级不良事件、总生存期和无进展生存期上均无显著差异。结论提示贝伐珠单抗剂量可能不影响卵巢癌结局,但存在样本量小和异质性的局限。

要点

  • 低剂量与高剂量贝伐珠单抗在部分缓解、完全缓解、客观缓解率上无显著差异。
  • 两组在≥3级不良事件、总生存期和无进展生存期上亦无显著差异。
  • 敏感性分析和亚组分析证实了主要分析结果。

核心结论

  • 间接治疗比较发现低剂量与高剂量贝伐珠单抗联合化疗在临床结局上无显著差异。
  • 尽管存在样本量小和异质性的局限,结果提示贝伐珠单抗剂量可能不影响卵巢癌结局。

研究设计与样本

  • 系统检索Embase、MEDLINE®和CENTRAL(2023年9月18日)纳入评估贝伐珠单抗对比任何治疗或对照的随机对照试验。
  • 共纳入6项随机对照试验进行间接治疗比较,样本量范围24-1528例患者。
  • 5项试验评估高剂量贝伐珠单抗联合化疗,共同对照为卡铂+紫杉醇。
  • 试验主要纳入III期(n=4)或II-III期(n=1)卵巢癌患者,一项未报告癌症分期。

主要发现

  • 部分缓解的风险比(95%置信区间)为0.66(0.42,1.02),低剂量组对比高剂量组。
  • 完全缓解的风险比为1.76(0.76,4.11),客观缓解率为1.01(0.63,1.61),疾病进展为1.08(0.38,3.10)。
  • 临床获益的风险比为0.89(0.76,1.03),任何≥3级不良事件为1.53(0.96,2.44)。
  • 总生存期的风险比为0.93(0.77,1.13),无进展生存期为1.02(0.86,1.22)。
  • 敏感性分析和亚组分析证实了主要分析结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出存在样本量小的局限性。
  • 原文指出存在异质性的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: First-line therapy for ovarian cancer involves cytoreductive surgery and platinum-based chemotherapy, with or without bevacizumab. Bevacizumab can be administered at low (7.5 mg/kg every three weeks [Q3W]) or high dose (15 mg/kg Q3W). This study compared the efficacy and safety of these dosing strategies. METHODS: Systematic literature review of Embase, MEDLINE®, and CENTRAL (18/09/2023) identified randomized controlled trials (RCTs) evaluating bevacizumab versus any therapy or control in ovarian, fallopian tube, or primary peritoneal cancer. Indirect treatment comparisons (ITC) of response, survival, and safety outcomes were performed, including sensitivity/subgroup analyses adjusting for heterogeneity. RESULTS: Six RCTs (sample size: 24-1528 patients) were included for ITC. Five evaluated high-dose bevacizumab with chemotherapy. The common comparator was carboplatin + paclitaxel. Trials mainly included stage III (n = 4) or stage II-III (n = 1) ovarian cancer patients; one did not report cancer stage. Primary analyses showed no significant differences between low- versus high-dose bevacizumab for partial response (risk ratio [95 % confidence interval]: 0.66 [0.42, 1.02]), complete response (1.76 [0.76, 4.11]), objective response rate (1.01 [0.63, 1.61]), progressive disease (1.08 [0.38, 3.10]), clinical benefit (0.89 [0.76, 1.03]), any grade ≥ 3 adverse event (1.53 [0.96, 2.44]), specific grade ≥ 3 adverse events, overall survival (hazard ratio: 0.93 [0.77, 1.13]), or progression-free survival (1.02 [0.86, 1.22]). Sensitivity and subgroup analyses confirmed findings. CONCLUSIONS: This ITC found no significant difference in clinical outcomes between low- and high-dose bevacizumab combination therapy. Despite limitations of small sample size and heterogeneities, findings suggest that bevacizumab dose may not significantly impact ovarian cancer outcomes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ethier JL, Shephard C, Granados DP, et al. Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison. Gynecol Oncol. 2025. PMID: 40132433. doi:10.1016/j.ygyno.2025.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。